Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
Le Gall JB, Milone MC, Waxman IM, Shaw LM, Harrison L, Duffy D, van de Ven C, Militano O, Geyer MB, Morris E, Bhatia M, Satwani P, George D, Garvin JH, Bradley MB, Schwartz J, Baxter-Lowe LA, Cairo MS. Le Gall JB, et al. Among authors: schwartz j. Bone Marrow Transplant. 2013 Jan;48(1):19-25. doi: 10.1038/bmt.2012.105. Epub 2012 Jun 11. Bone Marrow Transplant. 2013. PMID: 22684047 Clinical Trial.
Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases.
Bradley MB, Satwani P, Baldinger L, Morris E, van de Ven C, Del Toro G, Garvin J, George D, Bhatia M, Roman E, Baxter-Lowe LA, Schwartz J, Qualter E, Hawks R, Wolownik K, Foley S, Militano O, Leclere J, Cheung YK, Cairo MS. Bradley MB, et al. Among authors: schwartz j. Bone Marrow Transplant. 2007 Oct;40(7):621-31. doi: 10.1038/sj.bmt.1705785. Epub 2007 Jul 30. Bone Marrow Transplant. 2007. PMID: 17660841
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.
Styczynski J, Tallamy B, Waxman I, van de Ven C, Milone MC, Shaw LM, Harrison L, Morris E, Satwani P, Bhatia M, George D, Bradley MB, Garvin JH, Schwartz J, Baxter-Lowe LA, Cairo MS. Styczynski J, et al. Among authors: schwartz j. Bone Marrow Transplant. 2011 Jun;46(6):790-9. doi: 10.1038/bmt.2010.209. Epub 2010 Sep 6. Bone Marrow Transplant. 2011. PMID: 20818441 Clinical Trial.
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
Bhatia M, Jin Z, Baker C, Geyer MB, Radhakrishnan K, Morris E, Satwani P, George D, Garvin J, Del Toro G, Zuckerman W, Lee MT, Licursi M, Hawks R, Smilow E, Baxter-Lowe LA, Schwartz J, Cairo MS. Bhatia M, et al. Among authors: schwartz j. Bone Marrow Transplant. 2014 Jul;49(7):913-20. doi: 10.1038/bmt.2014.84. Epub 2014 May 5. Bone Marrow Transplant. 2014. PMID: 24797180 Clinical Trial.
Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients.
Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, George D, Bradley MB, Harrison L, Petrillo K, Schwartz J, Foley S, Hawks R, Baxter-Lowe LA, Cairo MS. Satwani P, et al. Among authors: schwartz j. Biol Blood Marrow Transplant. 2013 Apr;19(4):552-61. doi: 10.1016/j.bbmt.2012.12.005. Epub 2012 Dec 16. Biol Blood Marrow Transplant. 2013. PMID: 23253557 Free article.
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning.
Waxman IM, Militano O, Baldinger L, Roman E, Qualter E, Morris E, Garvin J, Bradley MB, Bhatia M, Satwani P, George D, Del Toro G, Hawks R, Wolownik K, Foley S, Cheung YK, Schwartz J, van de Ven C, Baxter-Lowe LA, Cairo MS. Waxman IM, et al. Among authors: schwartz j. Pediatr Transplant. 2009 Jun;13(4):464-74. doi: 10.1111/j.1399-3046.2008.01000.x. Epub 2008 Sep 10. Pediatr Transplant. 2009. PMID: 18785912
Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
Satwani P, Baldinger L, Freedman J, Jacobson JS, Guerra J, van de Ven C, Morris E, Garvin J, George D, Bradley MB, Bhatia M, Tallamy B, Schwartz J, Jin Z, Cairo MS. Satwani P, et al. Among authors: schwartz j. Biol Blood Marrow Transplant. 2009 Dec;15(12):1587-95. doi: 10.1016/j.bbmt.2009.08.006. Epub 2009 Sep 30. Biol Blood Marrow Transplant. 2009. PMID: 19896083 Free article.
A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P, Bhatia M, Garvin JH Jr, George D, Dela Cruz F, Le Gall J, Jin Z, Schwartz J, Duffy D, van de Ven C, Foley S, Hawks R, Morris E, Baxter-Lowe LA, Cairo MS. Satwani P, et al. Among authors: schwartz j. Biol Blood Marrow Transplant. 2012 Feb;18(2):324-9. doi: 10.1016/j.bbmt.2011.11.007. Epub 2011 Nov 9. Biol Blood Marrow Transplant. 2012. PMID: 22079471 Free article. Clinical Trial.
Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia.
McGuinn C, Geyer MB, Jin Z, Garvin JH, Satwani P, Bradley MB, Bhatia M, George D, Duffy D, Morris E, van de Ven C, Schwartz J, Baxter-Lowe LA, Cairo MS. McGuinn C, et al. Among authors: schwartz j. Pediatr Blood Cancer. 2014 Jul;61(7):1289-94. doi: 10.1002/pbc.24976. Epub 2014 Feb 12. Pediatr Blood Cancer. 2014. PMID: 24623601 Clinical Trial.
7,304 results